Home › Cerebral Hemorrhage › NCT06799390

Auricular VNS Following Intracerebral Hemorrhage

Vagus Nerve Stimulation Following Intracerebral Hemorrhage (IHC) to Mitigate ICH-induced Inflammation and Cerebral Edema

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients who present with a spontaneous supratentorial intracerebral hemorrhage (ICH) to Barnes Jewish Hospital

Exclusion Criteria:

* Patients \< 18 years old
* Patients with a presumed traumatic etiology for their ICH, infratentorial location, ICH volume \> 60 ml or \< 10 ml, at risk of imminent death (e.g. Glasgow Coma Scale, GCS of 3 or one or more pupils unreactive), surgical intervention imminently planned (not including ventriculostomy)
* Patients undergoing active cancer therapy
* Patients with sustained bradycardia on arrival with a heart rate \< 50 beats per minute.
* Patients who cannot be enrolled within 48 hours of the initial bleed.

About the study

This study will evaluate whether non-invasive auricular vagal nerve stimulation lowers inflammatory markers, and improves outcomes following intracerebral hemorrhage.

What is being tested

• Auricular Vagus Nerve Stimulation (device)
• Sham Auricular Vagus nerve Stimulation (device)

Sponsor: Washington University School of Medicine · Participants: 80 · Started: Apr 6, 2025

Contact the study team

• Raj Dhar, MD · Phone: 314-362 2999

Official record on ClinicalTrials.gov — NCT06799390

Locations in the U.S.

Conditions

• Cerebral Hemorrhage
• Brain Diseases
• Neurologic Diseases
• Vascular Diseases
• Bleeding

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.